shutterstock_1197703630 - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

ESMO 2019: Delegates told refractory metastatic renal cell carcinoma is an unmet need with great growth potential

According to expert opinion, 20─30% of patients with stage I–III localised tumours will relapse after nephrectomy and progress to stage IV metastatic RCC, which requires systemic drug therapy.